Hims & Hers Health (NYSE:HIMS) Shares Down 2.7%

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report)’s share price traded down 2.7% during trading on Friday . The company traded as low as $19.12 and last traded at $19.81. 2,679,134 shares traded hands during mid-day trading, a decline of 59% from the average session volume of 6,588,163 shares. The stock had previously closed at $20.37.

Analysts Set New Price Targets

Several research firms have issued reports on HIMS. Jefferies Financial Group reissued a “hold” rating and set a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Truist Financial boosted their price objective on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research note on Tuesday, February 27th. Piper Sandler raised their target price on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 7th. Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and upped their price target for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Finally, SVB Leerink started coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average target price of $15.69.

Read Our Latest Stock Analysis on Hims & Hers Health

Hims & Hers Health Trading Down 4.7 %

The firm has a market cap of $4.17 billion, a PE ratio of -1,942.00 and a beta of 0.97. The firm’s 50 day simple moving average is $14.45 and its 200 day simple moving average is $11.57.

Hims & Hers Health (NYSE:HIMSGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.05) EPS. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Irene Becklund sold 2,747 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $14.19, for a total transaction of $38,979.93. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Soleil Boughton sold 63,621 shares of Hims & Hers Health stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $15.17, for a total transaction of $965,130.57. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at approximately $2,341,413.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Irene Becklund sold 2,747 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $14.19, for a total transaction of $38,979.93. The disclosure for this sale can be found here. Insiders have sold 594,308 shares of company stock worth $8,464,914 over the last quarter. Insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently made changes to their positions in the company. Cetera Advisors LLC purchased a new position in shares of Hims & Hers Health during the first quarter valued at $396,000. Farallon Capital Management LLC grew its holdings in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. Virtu Financial LLC purchased a new position in Hims & Hers Health during the first quarter valued at approximately $638,000. Strategic Wealth Partners Ltd. bought a new position in Hims & Hers Health in the first quarter worth approximately $839,000. Finally, Bayesian Capital Management LP purchased a new stake in Hims & Hers Health during the first quarter worth $1,770,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Read More

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.